Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals,…
| Price | $32.31 |
|---|---|
| Market cap | $1.2B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | NASDAQ |
| 52-week range | 28.54-54.85 |
| Beta | 0.24 |
Explore HROW's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.